Driving Life Sciences Growth Through Supply Chain Resilience

Q: What is the scope of Arcera Life Sciences operations in Mexico, and how does it leverage its international operations to consolidate its presence in the country? 

A: Arcera is a life sciences company created in 2023 by ADQ, an Abu Dhabi-based sovereign investor.Our growth strategy is driven by the ambition to advance innovation by expanding our portfolio of differentiated therapies,  investing in the capabilities that let us deliver effectively, and scaling the business through partnerships and selective M&A. Sovereign backing affords us a long-term investment horizon and a clear roadmap for expanding within the pharmaceutical ecosystem. We focus on transformational healthcare solutions, particularly in life sciences and orphan diseases, across core therapeutic areas such as cardiometabolic health, central nervous system disorders, gastroenterology, and oncology.  

In Latin America, Arcera previously acquired Acino, a Swiss pharmaceutical company with operations in Central America and Ecuador, and subsequently acquired M8, which operates in Mexico and Brazil. While these combined operations form Arcera in Latin America, we maintain customer-facing brand equity, operating as M8 in Mexico and Acino in Central America, while building long-term awareness for Arcera among physicians, hospitals, and healthcare institutions. Rather than conducting internal R&D, our model accelerates growth through active M&A, business development, and strategic partnerships with global pharmaceutical leaders. 

Q: How does Mexico fit into Arcera’s broader global expansion strategy? 

A: Mexico serves as the anchor for our commercial strategy and product launches across Latin America. Its demographic scale and epidemiological profile align directly with our core therapeutic priorities. For example, Mexico faces significant health challenges regarding cardiometabolic conditions, including high rates of Type 2 diabetes and obesity. Our therapeutic focus and product pipeline, such as our partnership with South Korea’s Daewoong for the cardiometabolic treatment Abcito®, fit these population needs directly. Furthermore, Mexico acts as the primary bridge for transferring innovations from our global partners into Latin America, where products introduced and validated in Mexico are subsequently rolled out across Central America and other regional markets. 

Q: Why does Arcera prioritize cardiometabolic health, gastroenterology, and central nervous system disorders in Mexico? 

A: These priority areas address major unmet medical needs and access gaps in population health. Cardiometabolic health is driven by lifestyle factors, aging populations, and rising metabolic risks, where Mexico’s high prevalence of diabetes and obesity makes this a top priority. Central nervous system disorders encompass a wide range of conditions, where innovation offers significant opportunities to improve patient care across public and private 

sectors.

For gastroenterology, rapidly evolving clinical data highlights the gut-brain axis and its direct impact on mental and overall health. Beyond these pillars, we are expanding our portfolio into orphan diseases and oncology to deliver accessible, high-quality treatments.

Q: What upcoming treatments or product rollouts will Arcera launch in the region? 

A: Following the launch of Abcito®, we are introducing a new Type 2 diabetes treatment at the end of this year, which will expand into Central America shortly after. A new treatment targeting central nervous system disorders is scheduled for rollout around mid-2027, along with specialized pediatric support therapies. We are also expanding our gastroenterology portfolio and launching oncology and rare disease therapies across Latin America as regulatory approvals progress through authorities like COFEPRIS, ANVISA, and ARCSA. 

Q: How does Arcera’s long-term investment strategy enhance its competitive positioning in Latin America? 

A: Arcera’s long-term ownership structure gives us the opportunity to invest for sustainable growth, rather than reacting to short-term market fluctuations.  Our growth strategy includes partnerships with international pharmaceutical companies, selective acquisitions of regional assets, and the expansion of established portfolios cinto key markets such as Mexico, Brazil, and Colombia. Additionally,  we use advanced digital tools, including AI-driven supply chain analytics, to improve demand forecasting, optimize manufacturing, and secure access to active pharmaceutical ingredients.

Q: What role does your partnership with Fosun play in bringing global innovation to the region? 

A: Strategic partnerships, such as our collaboration with Fosun, establish a direct bridge for novel molecules, advanced medical technologies, , and AI-driven innovations from Asia to Latin America. By connecting global research hubs with our regional commercial network, we significantly shorten the time required to bring patented molecules to market. This framework allows us to serve both private retail pharmacy channels and public sector healthcare tenders efficiently. 

Q: How is Arcera leveraging global manufacturing capabilities to strengthen supply chain resilience in Mexico? 

A: In the modern volatile macroeconomic and geopolitical environment, supply chain resilience is essential, which Arcera addresses by combining multiple manufacturing plants across continents with centralized demand forecasting. Through integrated sales and operations planning alongside AI integration, we predict potential shortages of raw materials or APIs well in advance. Precise demand forecasting eliminates emergency air freight expenses and inventory losses, ensuring cost-efficient supply chains that protect patient access.

Q: How is nearshoring expected to shape pharmaceutical manufacturing in Mexico? 

A: Nearshoring represents a significant opportunity for Mexico, provided it is executed through genuine technological transfer rather than basic secondary packaging. For international companies to make major capital investments in local production facilities, there must be long-term policy stability with clear regulatory and fiscal frameworks, infrastructure reliability regarding energy and secure transport corridors, and export-oriented mandates so facilities built in Mexico supply the entire Latin American region rather than serving solely the domestic market. At Arcera, any future manufacturing footprint in Mexico would need to focus on high-value technology transfer and regional supply capability. 

Q: What regulatory improvements would help accelerate pharmaceutical investment and research in Mexico? 

A: Digitization is the single most impactful regulatory improvement needed across Latin America, as transitioning from physical paper dossiers to fully digital submission systems would significantly reduce processing bottlenecks and accelerate product availability for patients. We welcome COFEPRIS’s recent progress in implementing fast-track approval pathways for products already authorized by stringent regulatory authorities like the US FDA. Expanding these reliance mechanisms and streamlining clinical data reviews for novel therapies will encourage further investment in local clinical trials and speed up market access. 

Q: What are Arcera’s immediate strategic priorities for solidifying its market position in Mexico and Latin America? 

A: Our immediate priorities focus on four main operational pillars. The first is executing scheduled product launches in cardiometabolic health and CNS while introducing innovative patented molecules. The second is 

integrating independent country operations into a unified regional structure.

The third is utilizing digital targeting tools and commercial analytics to better equip sales teams and expand medical education initiatives. Finally, the fourth is partnering with healthcare providers to promote early diagnosis, patient education, and preventative lifestyle interventions alongside advanced pharmacological treatments.